What Is the 340B Rebate Model Pilot, and Why Is It Back Now? The 340B rebate model pilot is HRSA’s proposed replacement for upfront 340B discounts. Under this model, for a defined set of drugs, instead of getting the purchase price, covered entities would dispense at full price and then submit a rebate request to […]
340B Rebate Model Pilot: HRSA’s 2027 Comeback Read More »
340B rebate readiness is the operational capacity to identify, validate, submit, and reconcile claims under a rebate-based 340B model, then confirm that the rebate actually received matches what was owed. It is not the act of uploading a file once a month. Done correctly, it is a continuous cycle of data cleanup, exception handling, and
340B Rebate Readiness: Why the Five-Hour Myth Is Actually an Iceberg Read More »
What Did Arkansas Attorney General Tim Griffin Actually File? Arkansas Attorney General Tim Griffin filed suit against 22 defendants: 13 drug manufacturers, their related corporate entities, and data management firm Second Sight Solutions in Polk County Circuit Court. The complaint alleges the defendants engaged in deceptive business practices and violated Arkansas’ 2021 law requiring 340B-participating
Arkansas Sues Drugmakers Over 340B: What Covered Entities Should Know Read More »
340B mission impact is the outcome that results when a covered entity’s leadership makes intentional, defensible, and well-governed decisions about how to allocate 340B savings across competing needs. It is not automatic. Savings only become mission impact when leaders choose where the money goes and can prove why. That distinction sits at the center of
340B Mission Impact: How One Rural Health Center Turns Savings Into Real Patient Care Read More »
What Makes 340B Rural Health Centers Different From Large Urban Systems? 340B rural health centers differ from large urban systems primarily in delivery model: rural covered entities rely on networks of independent contract pharmacies rather than in-house pharmacy operations, because most rural clinic locations don’t have the patient volume to support one. That structural difference
What Is 340B Enrollment, and Why Does It Catch New Covered Entities Off Guard? 340B enrollment is the formal process by which an eligible healthcare provider registers with HRSA’s Office of Pharmacy Affairs Information System, known as OPAIS, to gain access to discounted outpatient drug pricing. It sounds like a paperwork exercise until a covered
340B Enrollment and Go-Live: What a New Covered Entity Actually Learns the Hard Way Read More »
Pharmacy leadership health equity is the operational practice of designing pharmacy strategy, workflows, and community partnerships so patients can access, afford, understand, and continue the care they are prescribed, especially across hospital discharge and ambulatory transitions. It matters because health equity is not achieved when a clinician writes a correct care plan; it is achieved
Bridging the Gap: How Pharmacy Leadership Drives Health Equity Read More »
What is Care Team Continuous Improvement? Care team continuous improvement is the ongoing, systematic effort to enhance the delivery, coordination, and outcomes of patient care by shifting from crisis-driven responses to proactive, data-informed strategies. In today’s complex healthcare landscape, home care and aging services are facing unprecedented challenges. The volume of aging adults requiring complex
Aging by Design: Protecting Your Family from Cognitive Crises Read More »
Duplicate discounts in 340B have become one of the most consequential issues shaping the program’s future. What once appeared to be a technical compliance concern has evolved into a broader debate about data transparency, manufacturer oversight, Medicaid managed care complexity, and the role of federal regulators. At the center of that debate is a fundamental
Rebate Pilot Blocked: Legal Limits in 340B’s Next Phase Read More »
340B mission impact is the patient and community outcome produced when program savings expand access, reduce pharmacy counter costs, and fund comprehensive safety-net services as Congress intended. It matters because the 340B Drug Pricing Program is increasingly debated as a financial and legal mechanism, while the statutory purpose, to stretch scarce federal resources and reach
Turning 340B Savings into Patient Access: The Mission Impact Debate Read More »
